This is a advisory committee whose proposer address (dE3h9GgLGEhpmTDx9eXdGkoT2SMJHo8ny2BLS4kgN6rSGeAkV) is shown in on-chain info below. Only this user can edit this description and the title. If you own this account, login and tell us more about your proposal.

Eli Lilly's new Alzheimer’s drug, donanemab, has shown significant promise in slowing cognitive decline by about 35% during early stages of the disease. The drug specifically targets toxic proteins that accumulate in Alzheimer’s patients' brains. These findings come after the US FDA granted full approval to another Alzheimer's drug, decanemab, marketed as LEQEMBI by Biogen and Eisai. Eli Lilly has now submitted donanemab for FDA approval, with a decision expected by year-end. This market resolves with “Yes” if donanemab receives FDA approval by the end of the year. It resolves “No” otherwise.

Advisory Committee Motion #42

No Active Proposals